Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.

Stefan R BornsteinDick de Zeeuw Hiddo J Lambers Heerspink Friedrich SchulzeLisa CroninArne WenzKatherine R Tuttle Samy Hadjadj Ellen Burgess

Published in: Diabetes, obesity & metabolism (2024)

BI 690517 was generally well tolerated, reduced plasma aldosterone and may decrease albuminuria in participants with diabetes and albuminuric chronic kidney disease.

Keyphrases

double blind
placebo controlled
chronic kidney disease
phase iii
phase ii
study protocol
clinical trial
end stage renal disease
type diabetes
cardiovascular disease
glycemic control
phase ii study
angiotensin ii
open label
randomized controlled trial
peritoneal dialysis
metabolic syndrome